The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: A network meta-analysis and benefit-risk assessment of finasteride and dutasteride

Journal of Dermatological Treatment

Volumn 25, Issue 2, 2014, Pages 156-161

  Gupta, Aditya K ^a,b   Charrette, Andrew ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

Alopecia; Hair loss; Randomized controlled trial; Systematic review; Treatment

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO;

DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HAIR; HUMAN; MALE TYPE ALOPECIA; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SELF EVALUATION; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; ALOPECIA; AZASTEROIDS; FINASTERIDE; HUMANS; MALE; PHOTOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SELF REPORT;

EID: 84890319168     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.813011     Document Type: Review

References (36)

1. Inui S, Itami S. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. J Dermatol Sci. 2011;61:1-6.
2. Zhuo FL, Xu W, Wang L, Wu Y, Xu ZL, Zhao JY. Androgen receptor gene polymorphisms and risk for androgenetic alopecia: A meta-Analysis. Clin Exp Dermatol. 2012;37:104-111.
3. Stoner E. The clinical development of a 5a-reductase inhibitor, finasteride. J Steroid Biochem. 1990;37:375-378.
4. Bayne EK, Flanagan J, Einstein M, Ayala J, Chang B, Azzolina B, et al. Immunohistochemical localization of types 1 and 2 5a-reductase in human scalp. Br J Dermatol. 1999;141:481-491.
5. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 45:S81-S86.
6. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5a-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55: 1014-1023.
7. Traish A. 5a-reductases in human physiology: An unfolding story. Endocr Prac. 2012;18:965-975.
8. Higgins JPT, Green S. editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]; The Cochrane Collaboration. 2008. Available from www.cochrane-handbook. org.
9. Barber B, Kaufman KD, Kozloff R, Girman CJ, Guess HA. A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatol Treat. 1998;9:181-186.
10. Van Valkenhoef G, Tervonen T, Zwinkels T, de Brock B, Hillege H. ADDIS: A decision support system for evidence-based medicine. 2012. Available from: Http://drugis.org/files/addis-dss.pdf (accessed on 20 April 2013
11. Van Valkenhoef G. Multicriteria benefit-risk assessment using network meta-Analysis. J Clin Epidemiol. 2012;65:394-403.
12. Brenner S, Matz H. Improvement in androgenetic alopecia in 53-76- year-old men using oral finasteride. J Dermatol. 1999;38:928-930.
13. Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41:550-554.
14. Eun HC, KwonOS, Yeon JH, ShinHS, KimBY, Ro BI, et al. Efficacy, safety and tolerability of dutasteride 0.5mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63: 252-258.
15. FDA Trial #089 [Internet]. FDA Approvals Package. 1997.Available from http://www.accessdata.fda.gov/drugsatfda-docs/nda/97/020788- propecia-Toc.cfm.
16. The Finasteride Male Pattern Hair Loss Study Group. Long-Term (5- year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12: 38-49.
17. GlaxoKlineSmith. GSK Trial ARI114263: A Study of the Efficacy and Safety of Multiple Doses of Dutasteride versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia [Internet]. GSK. 2012.Available from http://www.gsk-clinicalstudyregister. com.
18. Kawashima M, Hayashi N, Igarashi A, Kitahara H, Maeguchi M, Mizuno A, et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol. 2004;14:247-254.
19. Leavitt M, Perez-Meza D, Rao NA, Barusco M, Kaufman KD, Ziering C. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg. 2005;31:1268-1276.
20. Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40:930-937.
21. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5a-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55: 1014-1023.
22. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): Three-And 4-year results. J Am Acad Dermatol. 2006;55:71-74.
23. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, et al. Clinical dose ranging studies with finasteride a type 2a-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41:555-563.
24. Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol. 2002;12:32-37.
25. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6:9-13.
26. Van Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, Whiting D, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143:804-810.
27. Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003;13:150-160.
28. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review. Arch Dermatol. 2010;146:1141-1150.
29. Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia. Australas J Dermatol. 2013;54:49-51.
30. Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: A review of basic biology and their role in human diseases. Adv Urol. 2012;2012:1-18.
31. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747-1753.
32. Irwig MS. Persistent sexual side effects of finasteride: Could they be permanent? J Sex Med. 2012;9:2927-2932.
33. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73:1220-1223.
34. Merck Canada Inc. Propecia Product Monograph. 2012.
35. Kaufman KD. Long-Term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12:38-49.
36. Yamazaki M, Miyakura T, Uchiyama M, Hobo A, Irisawa R, Tsuboi R. Oral finasteride improved the quality of life of androgenetic alopecia patients. J Dermatol. 2011;38:773-777.